Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1...

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data...

Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates SAN JOSE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...